Source: Annual Congress 2006 - Various parenchymal lung diseases and pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Geltner, S. Ruescher, M. Stein, M. Kroell, H. Jamnig (Natters, Austria). Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application. Eur Respir J 2006; 28: Suppl. 50, 2280

Member's Comments

No comment yet.

Related content which might interest you: Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 1334-1335 Year: 2001 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 18: 247 Year: 2001 Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020 Initial dual oral combination therapy in pulmonary arterial hypertension Source: Eur Respir J 2016; 47:1727-1736 Year: 2016 Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution Source: Eur Respir J, 55 (6) 1902418; 10.1183/13993003.02418-2019 Year: 2020